New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
08:10 EDTNEPTNeptune Technologies files ITC complaint against competitors
Neptune Technologies & Bioressources announces that it has filed a complaint under Section 337 of the US Tariff Act of 1930 with the U.S. International Trade Commission, or ITC, alleging that Aker BioMarine AS, Aker BioMarine Antarctic USA, Aker BioMarine Antarctic AS, Enzymotec Limited, Enzymotec USA, Olympic Seafood AS, Olympic Biotec, Rimfrost USA, Bioriginal Food & Science, and Avoca, a division of Pharmachem Laboratories, are engaging in unfair trade practices by, at least, the importation, sale for importation, and sale after importation of certain krill-based products, namely krill paste and krill oils, that directly or indirectly infringe one or more claims of Neptune's U.S. Patent No. 8,278,351. Neptune is seeking an order prohibiting the respondents, their subsidiaries, related companies and agents from engaging in the importation, sale for importation, marketing and/or advertising, distribution, offering for sale, sale, sale after importation, or other transfer within the United States of certain krill-based products that infringe one or more claims of the '351 Patent. Neptune expects that the ITC investigation will formally commence within the next month or so, and that the case will take a total of about 15-18 months to conclude.
News For NEPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 20, 2015
07:34 EDTNEPTNeptune , NeuroBioPharm receive final court approval, completes arrangement
Subscribe for More Information
February 12, 2015
14:31 EDTNEPTNeuroBioPharm shareholders approve merger with Neptune
NeuroBioPharm, a subsidiary of Neptune Technologies & Bioressources, announces that its shareholders approved a resolution authorizing the previously announced plan of arrangement providing for, among other things, the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use